U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C17H15ClO4
Molecular Weight 318.752
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOFIBRIC ACID

SMILES

CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O

InChI

InChIKey=MQOBSOSZFYZQOK-UHFFFAOYSA-N
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

HIDE SMILES / InChI

Molecular Formula C17H15ClO4
Molecular Weight 318.752
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4500.0 nM [EC50]
1000.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FIBRICOR

Approved Use

FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (> 500 mg/dL); to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 μg/mL
105 mg 1 times / day single, oral
dose: 105 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
8.37 μg/mL
105 mg 1 times / day single, oral
dose: 105 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
162.96 μg × h/mL
105 mg 1 times / day single, oral
dose: 105 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
124.89 μg × h/mL
105 mg 1 times / day single, oral
dose: 105 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENOFIBRIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
105 mg 1 times / day steady-state, oral
dose: 105 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENOFIBRIC ACID serum
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (3.3%)
Diarrhea (3.9%)
Dyspepsia (3.7%)
Nausea (4.3%)
Fatigue (2%)
Pain (3.5%)
Nasopharyngitis (3.5%)
Sinusitis (3.3%)
Upper respiratory tract infection (5.3%)
ALT increased (1.2%)
Arthralgia (3.9%)
Back pain (6.3%)
Muscle spasms (1.6%)
Myalgia (3.3%)
Pain in extremity (4.5%)
Dizziness (4.1%)
Headache (12.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
ALT increased 1.2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Muscle spasms 1.6%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Headache 12.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Fatigue 2%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Constipation 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Myalgia 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Sinusitis 3.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Nasopharyngitis 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Pain 3.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Dyspepsia 3.7%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Arthralgia 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Diarrhea 3.9%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 4.1%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 4.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Pain in extremity 4.5%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Upper respiratory tract infection 5.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
Back pain 6.3%
135 mg 1 times / day multiple, oral
Recommended
Dose: 135 mg, 1 times / day
Route: oral
Route: multiple
Dose: 135 mg, 1 times / day
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
yes [IC50 2.2 uM]
yes [IC50 20 uM]
yes [IC50 282 uM]
yes [IC50 741 uM]
weak (co-administration study)
Comment: IC50 value from pre-incubation study; Coadministration with efavirenz (CYP2B6 substrate) resulted in AUC decrease of efavirenz by 12%
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
no
no
no
no
no
no
no
no
no
PubMed

PubMed

TitleDatePubMed
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
2001 Aug 24
Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson.
2001 Aug 24
A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.
2001 Feb
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
2001 Jun
Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.
2001 Nov
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.
2002 May 1
Update on fenofibrate.
2002 Winter
A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.
2003 Jan 24
Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
2004
A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
2004 Sep
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
2005 Feb
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
2005 Sep 2
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
2007
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.
2007 Aug
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
2008 Aug 15
An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.
2008 May 2
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
2009
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
2009
Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.
2009
Advances in the medical treatment of diabetic retinopathy.
2009 Aug
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.
2009 Aug
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
2009 Dec
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
2009 Feb 15
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
2009 Jan
Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.
2009 Jun
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
2009 May
Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.
2009 Nov
In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.
2009 Nov
Myopathy with statin-fibrate combination therapy: clinical considerations.
2009 Sep
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
2010
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
2010
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
2010 Apr
Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation.
2010 Jan
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:31:26 GMT 2025
Edited
by admin
on Mon Mar 31 18:31:26 GMT 2025
Record UNII
BGF9MN2HU1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOFIBRIC ACID
ORANGE BOOK   VANDF   WHO-DD  
Common Name English
FENOFIBRATE RELATED COMPOUND B
USP-RS  
Preferred Name English
PROCETOFENIC ACID
Common Name English
FIBRICOR
Brand Name English
FENOFIBRIC ACID [ORANGE BOOK]
Common Name English
FENOFIBRATE FREE ACID [MI]
Common Name English
FENOFIBRATE RELATED COMPOUND B [USP-RS]
Common Name English
PROPANOIC ACID, 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYL-
Common Name English
LF-153
Code English
FENOFIBRIC ACID [VANDF]
Common Name English
NSC-281318
Code English
FENOFIBRIC ACID [USP-RS]
Common Name English
Fenofibric acid [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175596
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
NCI_THESAURUS C98150
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
Code System Code Type Description
RXCUI
24852
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY RxNorm
FDA UNII
BGF9MN2HU1
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID8041030
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
PUBCHEM
64929
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
EVMPD
SUB34521
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
NSC
281318
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
CAS
42017-89-0
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
WIKIPEDIA
Fenofibric acid
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
RS_ITEM_NUM
1269436
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
CHEBI
83469
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
SMS_ID
100000128002
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
DAILYMED
BGF9MN2HU1
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
MERCK INDEX
m5279
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
RS_ITEM_NUM
1269618
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
ALTERNATIVE
ChEMBL
CHEMBL981
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
NCI_THESAURUS
C83804
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
MESH
C006012
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
DRUG BANK
DB13873
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
ECHA (EC/EINECS)
255-626-9
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY